A real-world study of Trifluridine/Tipiracil (TAS-102) combined with bevacizumab as the late-line treatment of metastatic colorectal cancer

Abstract Background Trifluridine/Tipiracil (TAS-102) is an effective agent for the late-line treatment of metastatic colorectal cancer (mCRC). Combining TAS-102 with bevacizumab improves outcomes but may increase adverse events. We conducted a real-world, retrospective, exploratory comparison of two...

全面介紹

書目詳細資料

Principais autores:	Shaocheng Zeng, Huangying Deng, Hanzhi Dong, Chunye Huang, Ruiwen Ruan, Xiaofeng Dai, Jianping Xiong, Jun Deng, Yangyang Yao
格式:	Artigo
語言:	Inglês
出版:	Springer 2026-02-01
叢編:	Discover Oncology
主題:	Trifluridine/Tipiracil Bevacizumab Metastatic colorectal cancer Prognostic analysis
在線閱讀:	https://doi.org/10.1007/s12672-026-04459-6
標簽:	添加標簽 沒有標簽, 成為第一個標記此記錄!